Wells Fargo Adjusts Price Target on Edwards Lifesciences
Wells Fargo analyst Larry Biegelsen maintained a buy rating on Edwards Lifesciences and raised the price target to $121 from $113.
Stocks · News reference
Edwards Lifesciences published a survey conducted by Talker Research highlighting a significant lack of awareness among caregivers regarding heart valve failure.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wells Fargo analyst Larry Biegelsen maintained a buy rating on Edwards Lifesciences and raised the price target to $121 from $113.
Royal Philips has announced that it will propose Todd J. Brinton, Chief Scientific Officer and Corporate Vice President at Edwards Lifesciences, as a new member of its Supervisory Board at the 2027 Annual General Meeting.
Edwards Lifesciences Corporation entered a consent judgment to resolve government allegations regarding premerger notification violations related to its acquisition of JC Medical.
Daiwa Securities has updated its price target for Edwards Lifesciences, raising it from $98 to $120.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
TD Cowen has adjusted its price target for Edwards Lifesciences to $121 from $117 and issued a sell rating on the stock.